EGFR and non-small cell lung carcinoma: For instance, the epidermal growth factor receptor (EGFR) is one of the driver mutations of NSCLC, and patients with advanced NSCLC have been treated with tyrosine kinase inhibitors targeting EGFR (EGFR-TKI) [2].